Rucaparib
- Generic Name
- Rucaparib
- Brand Names
- Rubraca
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18FN3O
- CAS Number
- 283173-50-2
- Unique Ingredient Identifier
- 8237F3U7EH
- Background
Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that la...
- Indication
Rucaparib is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
...
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer
- Associated Therapies
- Maintenance therapy
A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 41
- Registration Number
- NCT02505048
- Locations
- ๐ซ๐ท
Centre Leon Berard, Lyon, France
๐ซ๐ทInstitut Paoli Calmettes, Marseille, France
A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
- Conditions
- Interventions
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 19
- Registration Number
- NCT02042378
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
๐บ๐ธCedars Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธNew York University, New York, New York, United States
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
- Conditions
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 564
- Registration Number
- NCT01968213
- Locations
- ๐บ๐ธ
Saint Jude Heritage Medical Center, Fullerton, California, United States
๐บ๐ธUniversity of California Los Angeles (UCLA), Santa Monica, California, United States
๐บ๐ธJohns Hopkins Universty, Baltimore, Maryland, United States
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
- Conditions
- Interventions
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 136
- Registration Number
- NCT01482715
- Locations
- ๐ช๐ธ
Hospital Vall d'Hebron, Barcelona, Spain
๐ฎ๐ฑTel Aviv Sourasky Medical Center, Tel Aviv, Israel
๐ฌ๐งUniversity College London Cancer Institute, London, United Kingdom
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 135
- Registration Number
- NCT01074970
- Locations
- ๐บ๐ธ
Metro Health Cancer Care, Wyoming, Michigan, United States
๐บ๐ธPinnacle Health Fox Chase Regional Cancer Center, Harrisburg, Pennsylvania, United States
๐บ๐ธThe West Clinic, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.